BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+6.01%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.04B
AUM Growth
+$9.04B
(-3.5%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-1.97%
Top 10 Holdings %
Top 10 Hldgs %
81.82%
Holding
99
New
4
Increased
11
Reduced
16
Closed
9
Top Buys
| 1 |
Immunovant
IMVT
|
$64.1M |
| 2 |
Insmed
INSM
|
$28.5M |
| 3 |
Immunocore
IMCR
|
$24M |
| 4 |
Vaxcyte
PCVX
|
$22.4M |
| 5 |
Celcuity
CELC
|
$16M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$199M |
| 2 |
Krystal Biotech
KRYS
|
$26.6M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$25.4M |
| 4 |
CRISPR Therapeutics
CRSP
|
$22.3M |
| 5 |
Akero Therapeutics
AKRO
|
$22.2M |
Sector Composition
| 1 | Healthcare | 98.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Roivant Sciences
ROIV
$8.6B
| $38M | 0.42% |
3,767,773
| – | – |
|
27
Immatics
IMTX
$662M
| $32.8M | 0.36% |
7,275,830
| – | – |
|
28
Stoke Therapeutics
STOK
$1.08B
| $30.8M | 0.34% |
4,633,838
| – | – |
|
29
Cerus
CERS
$251M
| $26.9M | 0.3% |
19,351,087
-126,252
| -0.6% | -$175K |
|
|
30
Vaxcyte
PCVX
$4.17B
| $24.2M | 0.27% |
640,885
+592,000
| +1,211% | +$22.4M |
|
31
Monte Rosa Therapeutics
GLUE
$309M
| $22.8M | 0.25% |
4,916,095
| – | – |
|
|
32
CRISPR Therapeutics
CRSP
$4.82B
| $22.3M | 0.25% |
654,099
-653,912
| -50% | -$22.3M |
|
|
33
Akero Therapeutics
AKRO
$3.65B
| $22.2M | 0.25% |
548,713
-548,369
| -50% | -$22.2M |
|
34
Sera Prognostics
SERA
$129M
| $20.2M | 0.22% |
5,498,170
+63,771
| +1% | +$235K |
|
|
CNTA
35
Centessa Pharmaceuticals
CNTA
$2.13B
| $17.6M | 0.2% |
1,227,178
| – | – |
|
36
Neurogene
NGNE
$284M
| $17.4M | 0.19% |
1,486,200
+811,750
| +120% | +$9.51M |
|
37
IDEAYA Biosciences
IDYA
$2.26B
| $17.4M | 0.19% |
1,062,123
| – | – |
|
|
VRNA
38
Verona Pharma
VRNA
$9.18B
| $14.2M | 0.16% |
+223,843
| New | +$14.2M |
|
39
Candel Therapeutics
CADL
$281M
| $13.8M | 0.15% |
2,437,189
-544,794
| -18% | -$3.08M |
|
40
Praxis Precision Medicines
PRAX
$980M
| $12.6M | 0.14% |
331,533
| – | – |
|
|
TSVT
41
DELISTED
2seventy bio
TSVT
| $12.3M | 0.14% |
2,497,526
| – | – |
|
42
Xenon Pharmaceuticals
XENE
$2.99B
| $11.7M | 0.13% |
347,408
-646,271
| -65% | -$21.7M |
|
|
BCAX
43
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $10.9M | 0.12% |
833,333
| – | – |
|
44
Ionis Pharmaceuticals
IONS
$9.64B
| $10.8M | 0.12% |
357,915
| – | – |
|
|
DBVT
45
DBV Technologies
DBVT
$249M
| $9.97M | 0.11% |
1,461,425
| – | – |
|
|
ALMS
46
Alumis Inc. Common Stock
ALMS
$483M
| $9.59M | 0.11% |
1,562,500
| – | – |
|
47
Merus
MRUS
$5.04B
| $9.41M | 0.1% |
223,500
-226,500
| -50% | -$9.53M |
|
48
Prelude Therapeutics
PRLD
$69.1M
| $7.78M | 0.09% |
10,123,824
| – | – |
|
|
VERV
49
DELISTED
Verve Therapeutics
VERV
| $7.73M | 0.09% |
1,691,530
| – | – |
|
50
Rocket Pharmaceuticals
RCKT
$358M
| $7.32M | 0.08% |
1,097,079
+1,000,000
| +1,030% | +$6.67M |
|